Sionna Therapeutics Files S-1/A Amendment

Ticker: SION · Form: S-1/A · Filed: Feb 3, 2025 · CIK: 2036042

Sentiment: neutral

Topics: ipo, pharmaceutical, sec-filing

TL;DR

Sionna Therapeutics filed an S-1/A, signaling progress on their IPO. Get ready for potential biotech investment.

AI Summary

Sionna Therapeutics, Inc. filed an S-1/A amendment on February 3, 2025, for its initial public offering. The company, incorporated in Delaware, is based in Waltham, MA, and operates in the pharmaceutical preparations sector. This filing updates information related to its registration statement.

Why It Matters

This S-1/A filing indicates Sionna Therapeutics is moving forward with its IPO process, which could lead to new investment opportunities in the biotechnology sector.

Risk Assessment

Risk Level: medium — As a company in the pharmaceutical preparations sector undergoing an IPO, there are inherent risks associated with market volatility and the success of their drug development pipeline.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this S-1/A filing?

This S-1/A filing is an amendment to the initial S-1 registration statement, used by Sionna Therapeutics, Inc. to update information for its proposed initial public offering.

When was this amendment filed with the SEC?

This amendment was filed with the Securities and Exchange Commission on February 3, 2025.

Where is Sionna Therapeutics, Inc. headquartered?

Sionna Therapeutics, Inc.'s principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA 02451.

Who is listed as the President and Chief Executive Officer?

Michael Cloonan is listed as the President and Chief Executive Officer of Sionna Therapeutics, Inc.

What is the Standard Industrial Classification code for Sionna Therapeutics, Inc.?

The Primary Standard Industrial Classification Code Number for Sionna Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,547 words · 18 min read · ~15 pages · Grade level 13.7 · Accepted 2025-02-03 06:06:11

Key Financial Figures

Filing Documents

RISK FACTORS

RISK FACTORS 17 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 84

USE OF PROCEEDS

USE OF PROCEEDS 86 DIVIDEND POLICY 88 CAPITALIZATION 89

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 94

BUSINESS

BUSINESS 112 MANAGEMENT 169

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 180 DIRECTOR COMPENSATION 195 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 199 PRINCIPAL STOCKHOLDERS 203

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 207 SHARES ELIGIBLE FOR FUTURE SALE 213 MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES FOR NON-U.S. HOLDERS 215

UNDERWRITING

UNDERWRITING 220 LEGAL MATTERS 229 EXPERTS 229 WHERE YOU CAN FIND ADDITIONAL INFORMATION 229 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the U.S.: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the U.S. Persons outside of the U.S. who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the U.S. All trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto. -i- Table of Contents Market, Industry and Other Data The market data

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing